Andreas Niethammer
Keine laufenden Positionen mehr
Profil
Andreas Niethammer is the founder of Vaximm AG, which was founded in 2008.
He held former positions as Executive Medical Director at NantKwest, Inc., Vice President at Eli Lilly & Co., Vice President at Tocagen, Inc., Associate Professor at Ruprecht-Karls-Universität Heidelberg, and Vice President at Poseida Therapeutics, Inc.
Ehemalige bekannte Positionen von Andreas Niethammer
| Unternehmen | Position | Ende |
|---|---|---|
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01.01.2007 |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Gründer | - |
| POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| FORTE BIOSCIENCES, INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
